The MHRA authorised plozasiran, sold as Redemplo, on 19 October for adults with familial chylomicronaemia syndrome, a rare genetic disorder that drives dangerously high triglyceride levels and recurrent pancreatitis.
Patients will receive a 25 mg injection under the skin every three months alongside a low-fat diet, with training so they or carers can administer doses at home after specialist supervision.
Clinical evidence
Regulators based the decision on a study of 75 adults with FCS. All participants followed a controlled diet; 50 received plozasiran and 25 a placebo. After ten months, median triglyceride levels fell about 80% in the treatment group versus 17% on placebo, and acute pancreatitis episodes were fewer among treated patients.
Plozasiran blocks production of apolipoprotein C3, a liver protein that slows fat breakdown. Lowering that protein helps clear triglycerides from the bloodstream, reducing inflammation risk in the pancreas.
Side effects and monitoring
The most common side effect is hyperglycaemia, reported in more than one in ten patients. Other frequent issues include headache, nausea and injection-site reactions. MHRA executive director Julian Beach said the agency will continue safety monitoring through the Yellow Card scheme.
Specialist lipid clinics in England, Scotland, Wales and Northern Ireland will identify eligible patients, who remain rare even in a population of millions. NHS commissioning bodies will decide funding timelines; NICE appraisals often follow MHRA authorisations for high-cost orphan medicines.
Patient impact
FCS families have historically relied on extremely strict diets and hospitalisations when pancreatitis strikes. A quarterly injection does not cure the genetic defect but can reduce emergency admissions and chronic pain, improving school and work attendance for younger adults diagnosed in their twenties.
Charities representing pancreatic disorders welcomed the authorisation while urging clear referral pathways so GPs do not mistake symptoms for alcohol-related disease. With Redemplo on the market, the next policy debate is equitable access across UK nations—not whether the science merits a licence.
Pharmacist role
Community pharmacists may eventually support home injection training where specialist nurses are stretched, though initial doses are expected in hospital lipid clinics. Patient groups asked manufacturers to publish plain-language guides on diet compliance alongside the medicine, because triglyceride control still depends on nutrition.
Researchers are studying whether earlier intervention in adolescents with genetic lipid disorders could prevent chronic pancreatic damage; Redemplo's licence currently covers adults only, leaving paediatric data for future submissions.
Health economists will model whether quarterly injections reduce emergency pancreatitis admissions enough to offset drug costs in NHS budgets. Similar calculations followed authorisations for other orphan lipid medicines, often taking months before routine funding letters reach clinicians.
Patients' organisations urged GPs to refer people with possible FCS symptoms to specialist centres rather than relying on statins alone, which do not address the underlying chylomicronaemia driving triglyceride spikes. MHRA materials stress that Redemplo is not a substitute for dietary discipline, even when injections dramatically lower blood-fat readings on lab printouts.
Specialist nurses said training sessions for home injection will roll out regionally so patients outside London are not forced to travel monthly. Wales and Scotland issued statements welcoming the authorisation while their health boards assess formulary timing. Northern Ireland's Department of Health noted that rare-disease pathways already exist for lipid clinics in Belfast and said Redemplo would slot into those networks once pricing is agreed.